What You Should Know:
– Carta Healthcare®, which ignites healthcare improvement by unlocking the power of clinical data, expanded the strength and capabilities of its AI-powered platform with the acquisition of Realyze Intelligence.
– The Realyze Intelligence solution leverages AI to match patients to clinical trials to accelerate research and reduce costs while providing patients with the latest advances in care.
Carta Healthcare and Realyze Intelligence: Transforming Clinical Data Management with AI-Powered Solutions
Carta Healthcare and Realyze Intelligence are revolutionizing healthcare data abstraction and analysis by leveraging artificial intelligence (AI) to address inefficiencies and improve patient outcomes. Their advanced platforms combine clinician expertise with AI-driven automation to provide faster, cost-effective, and high-quality insights into clinical data for oncology and beyond.
Carta Healthcare’s AI-Driven Data Abstraction
Carta Healthcare addresses the challenges of clinical registry data abstraction—traditionally labor-intensive, time-consuming, and costly—through a blend of AI technology and skilled expert abstractors. This approach delivers:
- Faster and more efficient data abstraction.
- Cost-effective solutions without compromising data quality.
- Enhanced insights for clinical registries and quality performance programs across specialties like oncology and cardiovascular health.
Realyze Intelligence: Accelerating Oncology Research
Realyze Intelligence specializes in rapidly analyzing structured and unstructured electronic health record (EHR) data to streamline patient identification for clinical trials and research. Key features include:
- Clinician-trained AI capable of assembling patient cohorts in seconds.
- Proven results, such as UPMC Hillman Cancer Center matching seven times more patients to trials and doubling enrollment rates with Realyze’s software.
- Adoption by leading cancer centers, including Memorial Sloan Kettering Cancer Center, and recognition by the CancerX Accelerator Program.
Synergistic Solutions for Urgent Challenges
With cancer on track to surpass cardiovascular disease as the leading global cause of death, the need for robust, AI-enhanced solutions has never been greater. Challenges such as unstructured patient notes—where over 80% of trial criteria reside—are addressed by these platforms, significantly reducing manual efforts. Additionally:
- Only 7% of patients with cancer currently participate in clinical trials, though 50% would enroll if effectively recruited.
- Carta Healthcare and Realyze Intelligence expand trial feasibility, improve recruitment, and accelerate data abstraction for cancer and other registries.
Impact and Vision
By integrating clinician-trained AI with human oversight, Carta Healthcare and Realyze Intelligence deliver actionable insights, dramatically reduce labor demands, and enhance research capabilities. Brent Dover, CEO of Carta Healthcare, emphasized their shared mission: “We believe data is the single most important ingredient to improve healthcare. By maximizing insights from clinical data, we aim to transform care practices and patient outcomes.”
Through their combined innovations, Carta Healthcare and Realyze Intelligence are at the forefront of advancing clinical research, addressing global health challenges, and enabling precision medicine.
